Skip to content
10-Q

Quarterly Report

PROVECTUS BIOPHARMACEUTICALS, INC. PVCT

0001493152-26-022950

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 420.28M sh
Shares Diluted Q1 2026 · Mar 31, 2026 420.28M sh
Shares Diluted Q1 2026 · Mar 31, 2025 420.28M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$357.57K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.09M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $223.88K
Cash And Equivalents Q1 2026 · Mar 31, 2025 $390.44K
Stockholders Equity Q1 2026 · Mar 31, 2026 −$6.72M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$6.3M
Current Liabilities Q1 2026 · Mar 31, 2026 $7.24M
Current Liabilities Q1 2026 · Dec 31, 2025 $6.9M
Total Liabilities Q1 2026 · Mar 31, 2026 $7.31M
Total Liabilities Q1 2026 · Dec 31, 2025 $7M
Current Assets Q1 2026 · Mar 31, 2026 $460.39K
Current Assets Q1 2026 · Dec 31, 2025 $567.87K
Total Assets Q1 2026 · Mar 31, 2026 $577.58K
Total Assets Q1 2026 · Dec 31, 2025 $697.5K
Eps Diluted Q1 2026 · Mar 31, 2026 $0.00
Eps Diluted Q1 2026 · Mar 31, 2025 $0.00
Eps Basic Q1 2026 · Mar 31, 2026 $0.00
Eps Basic Q1 2026 · Mar 31, 2025 $0.00
Sga Expense Q1 2026 · Mar 31, 2026 $914.57K
Sga Expense restated Q1 2026 · Mar 31, 2025 $973.87K
Rd Expense Q1 2026 · Mar 31, 2026 $333.33K
Rd Expense restated Q1 2026 · Mar 31, 2025 $402.7K
Net Income Q1 2026 · Mar 31, 2026 −$1.29M
Net Income Q1 2026 · Mar 31, 2025 −$1.14M
Operating Income Q1 2026 · Mar 31, 2026 −$1.25M
Operating Income Q1 2026 · Mar 31, 2025 −$1.1M
Revenue Q1 2026 · Mar 31, 2025 $278.63K